Online Store

Original air date:  9/19/18. Obviousness of Antibodies and other Biologics
This Webinar will highlight several approaches that have proven effective to overcome obviousness challenges for biologic drug patents, and will include USPTO and practitioner perspectives and recommendations for how to handle obviousness rejections for antibody and other biologic technologies. Immunotherapeutic biologics, including antibodies and cell-based therapies of increasing complexity, are at the forefront of advanced therapies for cancer, Alzheimer’s Disease, and rheumatoid arthritis.  With patents to biologics subject to frequent patentability rejections and challenges during prosecution and in PTAB proceedings, and findings of obviousness being common, this webinar will give the audience an opportunity to discuss challenges and strategies from multiple perspectives--invaluable information for those obtaining and defending biologic patents before the USPTO and in court.
Presented by: Carla Mouta-Bellum of Arrigo, Lee, Guttman & Mouta-Bellum, LLP; Vanessa Ford of USPTO; Vicki Norton of Duane Morris LLP; and moderated by Nicholas Landau of  Bradley Arant Boult Cummings LLP